Char

ACQUIRED_RESISTANCE † Acquired Drug Resistance
List the drugs that the strain was shown to acquire resistance to during any follow-up DST (defined as previously identified susceptibility and subsequent resistance on follow-up DST). List each drug, separated by a comma, using the provided abbreviations with this dictionary. Char *Additional follow-up DST results can be entered following a similar format. †Acquired resistance can be reported in a separate row but is not necessary as it can be calculated by the data analyst with the above collected data. 
Regimen Information
Failure*
Treatment terminated or need for permanent regimen change of at least two anti-TB drugs because of:
(1) lack of conversion by the end of the intensive phase, or (2) bacteriological reversion in the continuation phase after conversion to negative, or (3) evidence of additional acquired resistance to fluoroquinolones or second-line injectable drugs, or (4) adverse drug reactions. Death A patient who dies for any reason during the course of treatment Lost to Follow-up A patient whose treatment was interrupted for 2 consecutive months or more.
WHO 2005 (Laserson) Outcome Definitions (if 2013 not possible) Outcome Definition
Cure
Completed treatment according to program protocol and has at least five consecutive negative cultures from samples collected at least 30 d apart in the final 12 mo of treatment. If only one positive culture is reported during that time, and there is no concomitant clinical evidence of deterioration, a patient may still be considered cured, provided that this positive culture is followed by a minimum of three consecutive negative cultures taken at least 30 d apart.
Complete
Completed treatment according to program protocol but does not meet the definition for cure because of lack of bacteriological results (i.e., fewer than five cultures were performed in the final 12 mo of treatment).
Failure
Treatment will be considered to have failed if two or more of the five cultures recorded in the final 12 mo of therapy are positive, or if any one of the final three cultures is positive. (Treatment will also be considered to have failed if a clinical decision has been made to terminate treatment early because of poor clinical or radiological response or adverse events). Death A patient who dies for any reason during the course of MDR/RR-TB treatment Lost to Follow-up A patient whose treatment was interrupted for two or more consecutive months for any reason without medical approval. • Respect the confidentiality of all data received. They will not attempt to identify patients, nor contact patients directly.
Example of an Initial Data Sharing Agreement (Can Be
• Respect the principle that the investigator continues to 'own' the data sent for inclusion in this analysis. When the data set is "cleaned" and preliminary analyses completed, a copy of the data set will be returned to the investigator.
• Perform data analysis that addresses the objectives specified in the attached study protocol only. Any additional analysis will be performed only after it has been approved by the investigator. For additional analyses that are closely related to these objectives, the investigator will be informed; approval will be assumed if the investigator does not reply within a specified interval. If the investigator has concerns or objections to any new analyses, these will be addressed and resolved before proceeding. Analyses to address completely novel objectives that have not been foreseen in the current study protocol must be actively approved by the investigator before these analyses are undertaken.
• Finish analyses and return the data to the investigator by the sunset date. This date will be the date by which the analyses must be completed, and any manuscript(s) prepared. The tentative sunset date to complete analyses, and prepare related manuscripts is [INSERT DATE]. If a manuscript is submitted, the data must be held until peer review is completed, and then up to 1 year after publication -to allow time for responses to the findings (e.g., letters to the editor). However, after the sunset date no further new analysis can begin without agreement to the extension of the sunset date by the investigator.
• Share results of analyses with the investigator, and all members of the IPD group at intervals described in the study protocol.
• Prepare draft and final reports of results for the project and prepare manuscript(s) of results for publication. All draft reports and manuscripts will be reviewed and approved by the investigator, and all members of the IPD group before submission. The authorship of these reports will be "The Collaborative Group for Meta-Analysis of Updated Individual Patient Data in MDR-TB", followed by a listing of all members -in alphabetic order. The corresponding author will be Dr.
Menzies of McGill.
The investigator agrees to:
• Verify whether they require approval from their local Research Ethics Board, depending on their institution's policy. If so, the investigator will obtain this approval before sending the data to the McGill group. No additional data will be collected from the patients, thus investigator will not need to obtain patients' consent for this analysis.
• Transfer a data file of information on all patients who were members of a cohort of MDR-TB patients which the investigator reported in earlier publications. This patient dataset will be rendered completely anonymous before forwarding this to the Montreal Chest Institute by removing all personal identifiers.
• Become a member of The Collaborative Group for Meta-Analysis of Updated 
